On 20 April, a group of researchers reported the development of a new molecule that can reduce brain inflammation and the number of amyloid plaques in Alzheimer’s disease (AD). Scientists tested the compound known as L1 in mouse models genetically predisposed to develop AD. Results showed that L1 had high affinity for beta-amyloid and metal ions. A significant reduction (up to 50%) of the levels of amyloid plaques was described in the brain of the treated mouse models. In addition, L1 alleviated the brain inflammation response and reduced the amount of tau aggregates surrounding the amyloid plaques. L1 also exhibited antioxidant properties. Findings were published in the journal ACS Chemical Neuroscience. The researchers are planning to evaluate the ability of L1 to have a beneficial effect on the learning and memory performance of AD mouse models.
Researchers develop a new molecule that can reduce levels of amyloid plaques in mouse models
20/04/2020